Global Recall, FSN and FSCA Reporting Obligations for Medical Devices in Egypt

1. Key takeaways

Egypt’s reporting duty for recall-type events has two dimensions. On the territorial dimension, companies must report recalls, field safety notices (FSN) and field safety corrective actions (FSCA) taking place globally. On the domestic dimension, they must report any incident monitored within the Arab Republic of Egypt. Both are addressed to the Medical Devices Safety Unit – Egyptian Pharmacovigilance Center (MDSU), with timeframes governed by the medical device vigilance system guideline. The obligation is established, in the form of a written commitment, already at the registration and re-registration stage (GL.CAMD.002 Section 8) and at the variation stage (GL.CAMD.003 Section 6.2).

2. Legal basis

The reporting duty draws on both registration-side guidelines and the vigilance guideline itself.

3. Expert insights

Insight 1: this is one of the few markets that writes global recalls into registration-stage duties.

The original text of GL.CAMD.002 Section 8 requires companies to report any recall, FSN or FSCA procedure taking place globally. This means that recall actions taken in other markets, including the Chinese mainland, the European Union and the United States, fall within the reporting scope even where Egyptian products are unaffected. Companies cannot filter by whether the action touches the Egyptian market; the statutory wording is global.

Insight 2: the recall system itself is listed among the general requirements.

Section 11, item 12 of the general requirements states that a recall system shall be applied; item 13 adds that the company must implement safety requirements. Together with the Section 8 reporting duty, these provisions form a complete chain of having a system, executing it, and reporting on it.

Insight 3: the responsible parties are both the foreign manufacturer and the importer.

Section 11, item 9 provides that the foreign manufacturer and the importer bear full responsibility for the effectiveness and technical safety of the device, and that any defect or hazard arising from use is borne by them. This connects directly with the subject of the recall reporting duty: manufacturer and importer stand as parallel responsible parties.

Insight 4: the variation-stage commitment widens the scope to any regulatory measure.

GL.CAMD.003 Section 6.2, item 4 requires the applicant to commit to reporting any regulatory measures related to device safety, including incidents, recalls, FSN or FSCA, whether they occur globally or within Egypt. The wording at the variation stage is broader than at registration, expanding from recall/FSN/FSCA events to any regulatory measure connected with device safety.

Insight 5: events following an FSN can move to the PSR, but the report must reach all affected authorities.

The PSR clause of GL.CAP.Care.040 provides that incidents described in an FSN that occur after the FSN has been published and the FSCA implemented need not be reported case by case; the manufacturer may agree a frequency and content for periodic summary reporting with MDSU, but the periodic summary report must be sent to all affected national competent authorities. This mechanism can markedly reduce duplicate reporting effort, but it requires prior agreement rather than unilateral adoption.

Insight 6: promotional samples also sit at the intersection with device safety.

GL.CAMD.007 Section 8, item 4 provides that only the Scientific Office may import samples for advertising and marketing purposes; the samples must be marked as advertising samples and not for sale, are checked by the Central Administration for Pharmaceutical Establishments Inspection, and require the full set of quality certificates according to their classification. If such samples are involved in a safety incident, the reporting obligations apply to them as well.

Insight 7: the commitment letter is the carrier of the duty, and breach lands on registration standing.

Because the obligation is written into registration and variation dossiers as a commitment letter, failure to report is not merely a vigilance violation; it can also affect the acceptance and approval of later registration, re-registration and variation applications. Section 10 of the registration guideline makes a positive opinion of the safety department one of the conditions for exemption from Scientific Committee re-evaluation at re-registration, and the two provisions reinforce each other.

4. Practical recommendations

The following measures operationalise the dual-dimension reporting duty.

1. Establish an internal notification mechanism for global recall events: any recall, FSN or FSCA in any market triggers an Egyptian reporting assessment.
2. Do not filter by impact on Egypt: the statutory wording is global in scope.
3. Document the recall system: Section 11.12 requires that a recall system shall be applied.
4. Clarify the parallel responsibility of manufacturer and importer: allocate reporting duties and timeframes in the agency agreement.
5. Issue the variation-stage commitment on the broader wording: any regulatory measures related to device safety.
6. Agree the PSR frequency with MDSU proactively after an FSN, and ensure the report reaches all affected authorities.
7. Include reporting compliance records in re-registration materials to support a positive safety department opinion.

5. Verification checklist

• □ An internal notification mechanism for global recalls / FSN / FSCA is established
• □ The reporting scope is set as global and is not filtered internally
• □ The recall system is documented and can be presented on request
• □ The division of responsibility between manufacturer and importer is agreed in the contract
• □ The variation-stage commitment is issued on the broader wording of any regulatory measures related to device safety
• □ After an FSN, the PSR frequency and content have been agreed with MDSU
• □ Reporting compliance records are archived for citation at re-registration

Regulatory information verified as of October 29, 2026. The recall reporting duties listed in this article follow the current text of EDREX: GL.CAMD.002 Version 2, Sections 8 and 11, and EDREX: GL.CAMD.003 Version 3, Section 6.2; reporting timeframes and the summary mechanism follow EDREX: GL.CAP.Care.040 Version 1.

• Egypt local support: GRZAN assists manufacturers from the Chinese mainland and overseas with EDA medical device registration, import approval and variation applications, including registration applicant pathway design (importing company, local factory, or Scientific Office), preparation for Scientific Committee evaluation, demonstration of free sale certificate routes from reference countries, Arabic labelling and instructions-for-use localization, and the setup of vigilance and periodic reporting systems.
• Service capabilities: product classification and risk grading (devices Class I–III, IVD Class A–D), registration and re-registration, applicability assessment for system registration and bundled registration, three-way variation classification, import approval and annual import plans, and support for vigilance reporting and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.